π¬ Breast Cancer Intelligence Digest β Week 2026-W43
HELEN-Trio 011 reports an anthracycline-free chemoimmunotherapy regimen raising pCR to 57.5% in stage II-III TNBC while clinicians debate its control arm, RT CHARM shows 16-fraction postmastectomy radiotherapy is noninferior with reconstruction, ESMO issues an updated metastatic breast cancer guideline, and an FDA colitis safety signal lands on CDK4/6 inhibitors.
β‘ TL;DR
π Publications
- Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505). β 898 patients with unilateral invasive breast cancer and planned reconstruction were randomized 1:1 to 50 Gy in 25 fractions over 5 weeks or 42.56 Gy in 16 fractions over 3 weeks
- Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial. β Multicenter randomized open-label phase 3 trial at 14 hospitals in China; 369 patients enrolled, 352 in the mITT population
- Differential impact of tumor-derived ESR1 mutations on elacestrant benefit in metastatic breast cancer. β Breast tumors carrying ESR1 mutations sequenced at Caris Life Sciences were studied (n=3,344), with whole-transcriptome sequencing in a subset (n=1,663)
π¦ Twitter / π¦ Bluesky
- HELEN-Trio 011 in Annals of Oncology: camrelizumab plus docetaxel-carboplatin raises pCR to 57.5% in stage II-III TNBC, and clinicians immediately challenge the chemotherapy-only control arm β 369 patients with stage II-III TNBC were randomized to docetaxel plus carboplatin with or without camrelizumab
- DESTINY-Breast11 EFS curves become a teaching case on reading late Kaplan-Meier drops at 4.5% event maturity β EFS HR was 0.56 but the confidence interval crosses 1, and the T-DXd to THP curve drops sharply around 32 months
- Update: NRG-BR002 published in JCO and the argument shifts to whether in-field failures, not distant spread, explain the negative result β Among 125 eligible patients, adding ablation to first-line systemic therapy did not improve progression-free survival (19.5 vs 23 months) or overall survival, and the trial did not advance to phase III
- FDA safety signal puts colitis β not just diarrhea β on the CDK4/6 inhibitor watchlist as adjuvant use expands β Clinicians note CDK4/6 inhibitors are already widely used and their expanding adjuvant role exposes more patients to these agents
- Next-generation CDK inhibitor review in JCI maps CDK4-selective and CDK2-directed strategies for HR+/HER2- breast cancer β The review covers next-generation CDK inhibitors in HR+/HER2- breast cancer, spanning CDK4-selective agents, CDK2-directed approaches and broader multi-CDK strategies
Full details below β
π What's Being Published
Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505). β Poppe Matthew M et al., J Clin Oncol
Between 2018 and 2021, 898 patients with unilateral invasive breast cancer and planned reconstruction were randomized 1:1 to 50 Gy in 25 fractions over 5 weeks or 42.56 Gy in 16 fractions over 3 weeks. At a median follow-up of 3.9 years, 825 patients were evaluable for the primary end point. The 24-month reconstruction complication rates were 12.3% (52/422) with hypofractionated PMRT and 10.2% (41/403) with conventional PMRT, an estimated difference of -2.1% (95% CI, -6.5 to 2.2). Thirty-six-month locoregional recurrence was 1.5% (95% CI, 0.7 to 3.2) with hypofractionated PMRT and 2.2% (95% CI, 1.1 to 4.3) with conventional PMRT, with no statistically significant difference. Regardless of arm, complications were more frequent with implant-only than with autologous reconstruction (odds ratio = 1.65).
Clinical bottom line: Women undergoing mastectomy with immediate or delayed reconstruction can be offered a three-week, 16-fraction postmastectomy radiotherapy course without accepting more reconstruction complications or more locoregional recurrence. Implant-only reconstruction carries higher complication odds in either arm.
Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial. β Jiao D et al., Ann Oncol
Of 369 enrolled patients, 352 formed the mITT population. Patients were randomized 2:1 to 6 cycles of docetaxel 75 mg/m2 plus carboplatin AUC=6, with or without camrelizumab 200 mg IV. The pCR rate was 57.5% (134/233) with camrelizumab-chemotherapy versus 45.4% (54/119) with chemotherapy alone, an absolute difference of 12.2% (95% CI, 1.4 to 22.9; one-sided P=0.014). Grade 3-4 treatment-related adverse events occurred in 24.9% (58/233) versus 21.8% (26/119), and no treatment-related deaths were reported.
Clinical bottom line: Adding camrelizumab to anthracycline-free docetaxel-carboplatin raises pCR in stage II-III TNBC. However, the trial used a chemotherapy-alone control arm, survival data are immature, and the population was China-only. The regimen is an alternative worth testing against KEYNOTE-522, not a replacement for it.
Differential impact of tumor-derived ESR1 mutations on elacestrant benefit in metastatic breast cancer. β Sledge George W et al., Clin Cancer Res
The analysis covered ESR1-mutated breast tumors sequenced at Caris Life Sciences (n=3,344), with whole-transcriptome sequencing available in a subset (n=1,663). ESR1-L536 mutated tumors had significantly shorter time on elacestrant than Y537 and D538G mutations (HR=2.089, p=0.001). Patients with multiple ESR1 mutations also had shorter time on treatment than those with a single mutation (adjusted HR=1.62, p=0.038). L536 tumors showed lower GREB1 expression and reduced enrichment of estrogen response pathways.
Clinical bottom line: In ER+ metastatic breast cancer, an ESR1 mutation should no longer be read as a single binary biomarker. L536 variants and multi-mutant tumors derive less benefit from elacestrant and should prompt consideration of alternatives.
DNA-Based Biomarkers as Predictors of Carboplatin Response in Neoadjuvant Treatment for Hormone Receptor Positive and Triple-Negative Breast Cancer. β Pladsen Arne V et al., Clin Cancer Res
In this trial, 187 patients with early, high-risk, HER2-negative cT2-4 tumors received 12 weekly paclitaxel with or without carboplatin, followed by four cycles of epirubicin and cyclophosphamide. In TNBC, pCR was 69% (24/35) with carboplatin versus 43% (16/37) with control (p = 0.036). Carboplatin prolonged event-free survival (p = 0.017), including in patients with a low genomic LOH fraction (p = 0.007). In HR+ disease, pCR was 15% (9/60) versus 11% (6/55) (p = 0.59), while low residual cancer burden rose from 16% (9/55) to 35% (21/60; p = 0.033). Among HR+ tumors, 5 of 8 HRD tumors attained pCR with carboplatin compared with 4 of 47 HRD-negative tumors (p = 0.002).
Clinical bottom line: This trial does not change carboplatin practice today. It does supply the first randomized signal that a low genomic LOH fraction selects TNBC patients who gain most from carboplatin, while HRD status is the better guide in aggressive HR+ disease.
π Every paper considered this week, including the ones that didnβt make it β
π£οΈ What People Were Discussing This Week
How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).
HELEN-Trio 011 in Annals of Oncology: camrelizumab plus docetaxel-carboplatin raises pCR to 57.5% in stage II-III TNBC, and clinicians immediately challenge the chemotherapy-only control arm
Adding camrelizumab to docetaxel-carboplatin significantly improved pCR in stage II-III TNBC, with a larger gain in PD-L1 CPS β₯1 patients and early EFS that does not yet separate. Tarantino frames the regimen, together with NeoPACT, as an anthracycline-sparing neoadjuvant option. Critics counter that both arms were anthracycline-free, so the trial tested the added benefit of camrelizumab rather than anthracycline omission. They also question the chemotherapy-only control arm after pembrolizumab approval in China, and note camrelizumab's limited access outside China and myelosuppression despite G-CSF prophylaxis. The open debate is whether the pCR gain justifies dropping anthracyclines before EFS matures.
Key numbers: pCR 57.5% vs 45.4%, one-sided P=0.014 Β· Absolute difference 12.2% (95% CI, 1.4 to 22.9) Β· PD-L1 CPS β₯1 pCR 69.8% vs 51.9% Β· 2-yr EFS 89.7% vs 86.4%, HR 0.67 (95% CI 0.34β1.33) Β· Grade 3β4 TRAEs 24.9% vs 21.8%
Discussed by: @PTarantinoMD, @ChandrakanthMv, @OncoAlert, @dr_yakupergun, @Dr_Oncologista, @Dr_ElvinaA, @ChandrakanthMv
Sources cited: Annals of Oncology
DESTINY-Breast11 EFS curves become a teaching case on reading late Kaplan-Meier drops at 4.5% event maturity
The DESTINY-Breast11 EFS curve for T-DXd β THP drops sharply around 32 months. However, the number at risk falls from 141 at 24 months to 14 at 33 months and just 2 at 42 months, so one event among few patients at risk produces a large step. Clinicians stress that censoring marks are not events and that, with only 4.5% EFS event maturity, interpretation remains preliminary. Faculty are separately weighing neoadjuvant T-DXd against post-neoadjuvant T-DXd for high-risk HER2+ early breast cancer.
Key numbers: EFS HR 0.56, CI crosses 1 Β· EFS event maturity 4.5%
Discussed by: @ChandrakanthMv, @weoncologists, @OncoAlert
Update: NRG-BR002 published in JCO and the argument shifts to whether in-field failures, not distant spread, explain the negative result
Adding ablation to first-line systemic therapy improved neither progression-free survival nor overall survival, and the trial did not advance to phase III. Burstein states that focal ablation of asymptomatic metastatic disease should not be standard of care. Radiation oncologists counter that most ablation-arm progressions were inside the treated field, and replies ask whether these were post-ablation imaging changes absent blinded central review or histology. Critics also note that brain metastases were excluded and that few patients had de novo disease. The debate is whether NRG-BR002 is a negative trial of the oligometastatic concept or of the ablation technique and its progression adjudication.
Key numbers: PFS 19.5 vs 23 months Β· Ablation arm: 20/60 progressed in field, 10 more elsewhere
Discussed by: @PTarantinoMD, @CJTsaiMDPhD, @jryckman3, @JCO_ASCO, @weoncologists, @womenofteal, @jryckman3
Sources cited: NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Lin⦠(Journal of Clinical Oncology, 2026)
FDA safety signal puts colitis β not just diarrhea β on the CDK4/6 inhibitor watchlist as adjuvant use expands
The new FDA safety signal concerns potentially serious colitis, neutropenic or non-neutropenic, which is distinct from familiar treatment-related diarrhea. Because adjuvant CDK4/6 inhibitor use is expanding, more patients are now exposed to these agents. The sources provide no incidence data, only a call for vigilance. The practical question is when persistent diarrhea on adjuvant abemaciclib or ribociclib should prompt stopping the drug and endoscopic evaluation rather than dose reduction and loperamide.
Discussed by: @dr_yakupergun, @DFCI_BreastOnc
Sources cited: Cure Today Β· OncLive
Next-generation CDK inhibitor review in JCI maps CDK4-selective and CDK2-directed strategies for HR+/HER2- breast cancer
A review in JCI maps next-generation CDK inhibitors in HR+/HER2- breast cancer, from CDK4-selective agents and CDK2-directed approaches to broader multi-CDK strategies. The review contains no primary trial data. CDK4/6 inhibitors remain central in hormone receptor-positive disease, and CDK4-selective inhibition appears at ESMO 2026 with FOURLIGHT-1. The open question is whether progression on a CDK4/6 inhibitor should lead to a CDK4-selective or CDK2-directed agent, or to a SERD combination or ADC.
Discussed by: @DFCI_BreastOnc, @nicolobattisti
Sources cited: Advances in Systemic Treatment of Breast Cancer (New England Journal of Medicine, 2026)
Camizestrant gets FDA accelerated approval with a CDK4/6 inhibitor for ESR1-mutated HR+/HER2- advanced breast cancer on SERENA-6
The FDA granted accelerated approval to camizestrant plus a CDK4/6 inhibitor for ESR1-mutated HR-positive, HER2-negative advanced breast cancer. The approval rests on SERENA-6, where median PFS was 16 months, up from 9.2 months on an aromatase-inhibitor regimen. Camizestrant is listed among the FDA's 22 new drug approvals in Q3 2026. Because ESR1 mutations emerge under aromatase inhibitor pressure, clinicians are debating whether this justifies routine serial ctDNA monitoring on first-line aromatase inhibitor plus CDK4/6 inhibitor therapy.
Discussed by: @dr_yakupergun, @MeDucationai
Sources cited: FDA new drug approvals in Q3 2026 (Nature Reviews Drug Discovery, 2026) Β· Annals of Oncology
Elacestrant benefit splits by ESR1 variant: L536 and multi-mutant tumors come off treatment sooner in a 3,344-tumor Caris analysis
In a retrospective Caris analysis, L536 carriers and patients with multiple ESR1 mutations stayed on elacestrant for a shorter time than those with other variants or a single mutation. The endpoint is claims-based time on treatment, not PFS or OS. The proposed mechanism, reduced ER pathway activation, is hypothesized rather than proven. Commenters tie variant-specific SERD selection to repeat ctDNA testing at each progression and ask whether these profiles should steer patients away from elacestrant.
Key numbers: L536 vs Y537/D538G time on treatment HR=2.089, p=0.001 Β· Multiple vs single ESR1 mutation adjusted HR=1.62, p=0.038
Discussed by: @dr_yakupergun, @MeDucationai
Sources cited: Differential impact of tumor-derived ESR1 mutations on elacestrant benefit in metastatic⦠(Clin Cancer Res) · Annals of Oncology
Radiotherapy-plus-ADC safety meta-analysis: T-DM1 is the only ADC with a consistent radiation necrosis signal during intracranial radiotherapy
A systematic review and meta-analysis of 29 studies including 3,817 patients evaluated concurrent radiotherapy with T-DM1, T-DXd and sacituzumab govitecan. Severe extracranial toxicities were uncommon with all three agents. Intracranial radiotherapy, however, showed a consistent radiation necrosis signal with T-DM1 that was not observed with T-DXd or sacituzumab govitecan. The findings support updated ESTRO consensus recommendations and raise the question of whether concurrent brain radiotherapy should now be held specifically for patients on T-DM1.
Discussed by: @Icro_Meattini, @to_be_elizabeth, @weoncologists
ESMO 2026 breast previews converge on NATALEE OS, FINER, VIKTORIA-1, TALENT and KEYNOTE-B49
ESMO 2026 breast previews list OS from NATALEE, postMONARCH and FINER; CDK4 inhibition with FOURLIGHT-1; pembrolizumab in HR+ disease with KEYNOTE-B49; neoadjuvant T-DXd in TALENT; and ADC after ADC in SWITCH. Other previews add VIKTORIA-1 for AKT/PI3K pathway targeting and PANKU-Breast01 among bispecific ADC readouts. Clinicians are asking which readout, NATALEE overall survival or TALENT, is most likely to change practice.
Discussed by: @nicolobattisti, @ChandrakanthMv, @MarioBalsaMD
Sentinel lymph node biopsy after neoadjuvant chemotherapy in locally advanced breast cancer published in JCO, and surgeons ask how far axillary de-escalation can go
JCO published a study of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients presenting with locally advanced breast cancer. Surgical commentary frames de-escalation as less surgery only when staging remains accurate, which requires better selection, mapping and technique. The debate is whether sentinel node biopsy alone is defensible in converted node-positive disease, or whether axillary dissection is still required as prospective data mature.
Discussed by: @JCO_ASCO, @ozdogan_md
Sources cited: Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients Presenting With Loc⦠(Journal of Clinical Oncology, 2026)
π₯ Top Ranked Tweets
Sara Tolaney @stolaney1
RT @NCIDirector: Good news on #MetastaticBreastCancerAwarenessDay: A new Phase 3 pill combo kept tumors stable for nearly double the time for certain types of advanced breast cancer (10 months vs 5.5 months in ER+/HER2-) Nice work @DanaFarber and team! https://t.co/Oshqcw72PQ https://t.co/tG3lwt1GeX
π 3 β€οΈ 29 π 1 π 1,619
Janice Cowden @JaniceTNBCmets
RT @OncoAlert: FDA NEWSπΊπΈ HER2CLIMB-05 Update in #BreastCancer
On October 7, 2026, the FDA approved tucatinib with trastuzumab and pertuzumab as maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer after induction therapy. In HER2CLIMB-05, tucatinib significantly improved median PFS versus placebo (24.9 vs 16.3 months; HR 0.64, p<0.0001) in 654 patients, including those with brain metastases. OS data were immature.
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H
@nataliagandur @acampsmalea @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD
π 1 β€οΈ 25 π 15 π 4,122
ClinicalOncologyNews @ClinOncNews
Camizestrant earns FDA accelerated approval with a CDK4/6 inhibitor for ESR1-mutated HR-positive, HER2-negative advanced breast cancer. https://t.co/8CLgfyj22C https://t.co/cmIPQxcaT1
π 0 β€οΈ 2 π 0 π 108
ClinicalOncologyNews @ClinOncNews
FDA grants accelerated approval to camizestrant plus a CDK4/6 inhibitor for ESR1-mutated HR+/HER2β breast cancer. SERENA-6 showed median PFS of 16 months, up from 9.2 months on an aromatase-inhibitor regimen.
https://t.co/kNtKyUXWMt
#BreastCancer #ESR1 #FDAApproval https://t.co/ySFGyMEVCS
π 0 β€οΈ 0 π 0 π 136
Aya Mohamed | MSc, MD π @Dr_Oncologista
Metastatic #BreastCancer :
The #ESMO26 Clinical Practice Guideline for Diagnosis, Treatment and Follow-up
https://t.co/zc9xeG51eD
@OncoAlert @myESMO #BCSM
π 28 β€οΈ 48 π 11 π 3,132
Gil Morgan, MD @weoncologists
RT @mirrorsmed: 𧬠Are we fully translating the latest evidence into personalised care for metastatic breast cancer?
https://t.co/2Sd66QsbjQ
Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
The updated ESMO Clinical Practice Guidelinesπ highlight how molecular profiling, evolving treatment options and multidisciplinary decision-making are shaping the management of metastatic breast cancer.
β For clinicians and researchers, the challenge is not simply knowing which treatments are availableβbut determining the right treatment, for the right patient, at the right time, while protecting quality of life. #BreastCancer
@E_de_Azambuja
@curijoey
@RebeccaDSing
@LoiSher
@BarbaraPistill2
@TanjaSpanic
@stolaney1
@PeterSchmidMD
@LMU_Muenchen
@ALEDIGNUS12
@Prof_Nadia_H
π 8 β€οΈ 21 π 8 π 1,119
OncoAlert @OncoAlert
RT @mirrorsmed: 𧬠Are we fully translating the latest evidence into personalised care for metastatic breast cancer?
https://t.co/2Sd66QsbjQ
Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
The updated ESMO Clinical Practice Guidelinesπ highlight how molecular profiling, evolving treatment options and multidisciplinary decision-making are shaping the management of metastatic breast cancer.
β For clinicians and researchers, the challenge is not simply knowing which treatments are availableβbut determining the right treatment, for the right patient, at the right time, while protecting quality of life. #BreastCancer
@E_de_Azambuja
@curijoey
@RebeccaDSing
@LoiSher
@BarbaraPistill2
@TanjaSpanic
@stolaney1
@PeterSchmidMD
@LMU_Muenchen
@ALEDIGNUS12
@Prof_Nadia_H
π 8 β€οΈ 21 π 8 π 1,119
OncoAlert @OncoAlert
RT @Dr_Oncologista: Metastatic #BreastCancer :
The #ESMO26 Clinical Practice Guideline for Diagnosis, Treatment and Follow-up
https://t.co/zc9xeG51eD
@OncoAlert @myESMO #BCSM
π 42 β€οΈ 75 π 23 π 6,476
Dana-Farberβs Breast Oncology Center @DFCI_BreastOnc
RT @DanaFarber: Patients with estrogen-receptor-positive (ER+) HER-2-negative advanced breast cancer experienced significantly improved progression-free survival when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist, compared to a standard combination approach.
Recently published in @NEJM, these findings come from the phase 3 evERA Breast Cancer study, led by Principal Investigator @elmayermd. Read more: https://t.co/atpO7MVr7b
π 2 β€οΈ 20 π 10 π 2,088
Rebecca Shatsky, MD @Dr_RShatsky
RT @JCO_ASCO: Now out in #JCO!
NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer. Co-authored by @Docace911
Read the article. https://t.co/em3jPJiyoi
#BreastCancer #bcsm https://t.co/5OCUJGBJ1n
π 6 β€οΈ 16 π 12 π 5,223
Sara Tolaney @stolaney1
RT @DanaFarber: Patients with estrogen-receptor-positive (ER+) HER-2-negative advanced breast cancer experienced significantly improved progression-free survival when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist, compared to a standard combination approach.
Recently published in @NEJM, these findings come from the phase 3 evERA Breast Cancer study, led by Principal Investigator @elmayermd. Read more: https://t.co/atpO7MVr7b
π 2 β€οΈ 20 π 10 π 2,088
MV Chandrakanth @ChandrakanthMv
HELEN-Trio 011 | Positive Phase III Trial β But Is It Practice-Changing?
A promising result in early triple-negative breast cancer (TNBC).
β The good news:
Adding camrelizumab to docetaxel + carboplatin significantly improved pCR.
57.5% vs 45.4% (P = 0.014, one-sided)
But 5 important questions remain:
1. Availability: Camrelizumab has limited access outside China, including India.
2. Anthracyclines: Can we safely omit them? Not yet established.
3. Survival: No statistically significant EFS benefit demonstrated; OS benefit remains unproven.
4. Toxicity: Myelosuppression remains relevant despite G-CSF prophylaxis.
5. Generalisability: All patients were recruited in China.
π― Take-home:
Better pCR is encouraging, but it does not automatically establish better survival.
KEYNOTE-522 remains the established standard.
HELEN-Trio 011 is an important step towards anthracycline-free treatment, but not yet a proven replacement.
π Reference: HELEN-Trio 011, Annals of Oncology, 2026.
#MVOnco #BreastCancer #TNBC #HELENTrio011 #Immunotherapy #Oncology
π 5 β€οΈ 15 π 7 π 921
MV Chandrakanth @ChandrakanthMv
HELEN-Trio 011 | Can We Treat TNBC Without Anthracyclines?
A promising phase III trial β but is it practice-changing?
Part 1 β The Big Question
Can we simplify neoadjuvant treatment for stage IIβIII TNBC by avoiding anthracyclines?
Part 2 β The Good News
Adding camrelizumab to docetaxelβcarboplatin significantly improved pCR:
57.5% vs 45.4% (P = 0.014, one-sided).
Part 3 β The Survival Question
2-year EFS: 89.7% vs 86.4%
HR 0.67 (95% CI 0.34β1.33).
Encouraging, but not statistically significant. Severe toxicity was manageable.
Part 4 β Why NOT Practice-Changing?
- No direct comparison with KEYNOTE-522.
- Survival benefit remains unproven.
- Anthracycline omission has not been proven noninferior.
- Apparent safety advantages require direct comparison.
My Take-Home:
Improving pCR is encouraging. But before removing anthracyclines from a curative regimen, we need confidence that long-term outcomes are preserved.
Promising de-escalation. Not yet practice-changing.
π Reference: Jiao D et al. HELEN-Trio 011. Annals of Oncology, 2026.
DOI: https://t.co/otwbvTiW2N
#MVOnco #BreastCancer #TNBC #HELENTrio011 #Immunotherapy #OncologyResearch
π 13 β€οΈ 21 π 8 π 1,006
Aya Mohamed | MSc, MD π @Dr_Oncologista
Encouraging results for anthracycline-free chemoimmunotherapy in TNBC.
The key question is whether the pCR benefit translates into durable EFS/OS gains and how this approach compares with KEYNOTE-522. Long-term data will be critical.
@OncoAlert #TNBC #BreastCancer
[Quoting @PTarantinoMD: In @Annals_Oncology, results from a new phase 3 trial (HELEN Trio011 π¨π³) showing improved pCR with PD1-blockade added to carbo/taxotere for TNBC. Together with NeoPACT, these results offer an alternative, anthracycline-sparing neoadjuvant regimen for TNBC. https://t.co/PYi9N20egB https://t.co/Zp3VC6S697]
π 6 β€οΈ 36 π 7 π 1,939
Mustafa ΓzdoΔan, MD @ozdogan_md
#OncologyMovesFast
#HER2 is no longer just positive or negative. In the HER2-low group of DESTINY-Breast06, median progression-free survival was 13.2 months with T-DXd vs 8.1 months with chemotherapy. HER2-ultralow subgroup findings require separate, cautious interpretation.
#BreastCancer #FiveYearsInOncology
π 0 β€οΈ 11 π 6 π 621
π§ͺ Newly Recruiting Trials
3 trials (2 phase III, 1 phase II) opened this week, testing trastuzumab deruxtecan, surgery and radiation (SBRT) and ATX-898
Phase 3 Β· Daiichi Sankyo Β· trastuzumab deruxtecan Β· Maryland, Nevada, Tennessee, Texas Β· CT.gov β
Phase 3 Β· SWOG Cancer Research Network Β· surgery and radiation (SBRT) Β· Arkansas, Connecticut, Florida, Illinois, Iowa, Kansas +7 more Β· CT.gov β
Phase 1/2 Β· Antares Therapeutics, Inc Β· ATX-898 Β· Texas, Utah, Virginia Β· CT.gov β
Open all 3 on the trials page β
Agent descriptions from the NCI Thesaurus.
Prepared by Rafael Santana-Davila, M.D. Questions or feedback? Just reply to this email.
Disclaimer: This digest is AI-generated. Content may contain errors -- always verify with original sources.
Know a colleague who would find this useful? Just forward them this email.
☕ Not funded by anyone — no sponsors, no pharma. Buy me a coffee if it's useful.